1. Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration.
- Author
-
Hanhart, Joel, Comaneshter, Doron S., Dror, Yossi Freier, Vinker, Shlomo, and Freier Dror, Yossi
- Subjects
RETINAL degeneration treatment ,BEVACIZUMAB ,AGE factors in retinal degeneration ,SOCIODEMOGRAPHIC factors ,COMORBIDITY ,FOLLOW-up studies (Medicine) ,NEOVASCULARIZATION inhibitors ,VASCULAR endothelial growth factor antagonists ,INJECTIONS ,LONGITUDINAL method ,RETINAL degeneration ,VISUAL acuity ,RETROSPECTIVE studies ,CASE-control method ,ODDS ratio ,THERAPEUTICS - Abstract
Background: The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD.Methods: We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables.Results: During follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P < .001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C.I. 1.54-1.84), P < .001.Conclusions: We found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF